Pitching A Stent Amid The Hype: Cypher, Taxus Programs In 2003 And Beyond
This article was originally published in The Gray Sheet
Executive Summary
Patient and physician demand for drug-eluting stents in the U.S. has played an inimitable role in shaping the cardiovascular device market over the past year - and has set the stage for a stirring competition between the Cypher and Taxus stents
You may also be interested in...
Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004
Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull
Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004
Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull
Taxus Clears Legal Hurdle As Judge Denies J&J/Cordis Injunction Request
The arguments made by Boston Scientific and Johnson & Johnson/Cordis in the ongoing drug-eluting stent patent dispute both have merit, according to Wilmington, Del. federal court Judge Sue Robinson